Reduced Neutralization of SARS-CoV-2 Omicron Variant by Vaccine Sera and Monoclonal Antibodies
Open accessAbstract
Due to numerous mutations in the spike protein, the SARS-CoV-2 variant of concern Omicron (B.1.1.529) raises serious concerns since it may significantly limit the antibody-mediated neutralization and increase the risk of reinfections. While a rapid increase in the number of cases is being reported worldwide, until now there has been uncertainty about the efficacy of vaccinations and monoclonal antibodies. Our in vitro findings using authentic SARS-CoV-2 variants indicate that in contrast to the currently circulating Delta variant, the neutralization efficacy of vaccine-elicited sera against Omicron was severely reduced highlighting T-cell mediated immunity as essential barrier to prevent severe COVID-19. Since SARS-CoV-2 Omicron was resistant to casirivimab and imdevimab, genotyping of SARS-CoV-2 may be needed before initiating mAb treatment. Variant-specific vaccines and mAb agents may be required to treat COVID-19 due to Omicron and other emerging variants of concern.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Higher neutralizing activity was observed after a booster dose.
“Higher neutralizing activity was observed after a booster dose.”
From Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern (2021) · cites this paper as [4]
These findings are consistent with neutralization data for the omicron variant.
“These findings are consistent with neutralization data for the omicron variant.”
From Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern (2021) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
A novel coronavirus from patients with pneumonia in China, 2019
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244 · see citing works
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969 · see citing works
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286 · see citing works
SARS-CoV-2 variants, spike mutations and immune escape
Harvey, W. T., Carabelli, A. M., Jackson, B., Gupta, R. K., Thomson, E. C., Harrison, E. M., Ludden, C., Reeve, R., Rambaut, A., COVID-19 Genomics UK (COG-UK) Consortium, et al. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-021-00573-0 · Cited by 3,528 · see citing works
Coronavirus biology and replication: implications for SARS-CoV-2
V’kovski, P., Kratzel, A., Steiner, S., Stalder, H., & Thiel, V. (2020) · Nature Reviews Microbiology · doi:10.1038/s41579-020-00468-6 · Cited by 3,175 · see citing works
Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche
Kärber, G. (1931) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/bf01863914 · Cited by 3,074 · see citing works
Detection of a SARS-CoV-2 variant of concern in South Africa
Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E. J., Msomi, N., et al. (2021) · Nature · doi:10.1038/s41586-021-03402-9 · Cited by 2,510 · see citing works
Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies
Cao, Y., Wang, J., Jian, F., Xiao, T., Song, W., Yisimayi, A., Huang, W., Li, Q., Wang, P., An, R., et al. (2022) · Nature · doi:10.1038/s41586-021-04385-3 · Cited by 2,006 · see citing works
Data, disease and diplomacy: GISAID's innovative contribution to global health
Elbe, S., & Buckland‐Merrett, G. (2017) · Global Challenges · doi:10.1002/gch2.1018 · Cited by 1,928 · see citing works
Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa
Viana, R. P. E. S., Moyo, S. M., Amoako, D. G., Tegally, H., Scheepers, C., Althaus, C. L., Anyaneji, U. J., Bester, P. A., Boni, M. F., Chand, M., et al. (2022) · Nature · doi:10.1038/s41586-022-04411-y · Cited by 1,653 · see citing works
SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies
Barnes, C. O., Jette, C. A., Abernathy, M. E., Dam, K.-M. A., Esswein, S. R., Gristick, H. B., Malyutin, A. G., Sharaf, N. G., Huey-Tubman, K. E., Lee, Y. E., et al. (2020) · Nature · doi:10.1038/s41586-020-2852-1 · Cited by 1,599 · see citing works
Considerable escape of SARS-CoV-2 Omicron to antibody neutralization
Planas, D., Saunders, N., Maes, P., Guivel-Benhassine, F., Planchais, C., Buchrieser, J., Bolland, W.-H., Porrot, F., Staropoli, I., Lemoine, F., et al. (2022) · Nature · doi:10.1038/s41586-021-04389-z · Cited by 1,514 · see citing works
Cele, S., Jackson, L., Khoury, D. S., Khan, K., Moyo-Gwete, T., Tegally, H., San, J. E., Cromer, D., Scheepers, C., Amoako, D., et al. (2021) · doi:10.1101/2021.12.08.21267417 · Cited by 1,333 · see citing works
Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity
Meng, B., Abdullahi, A., Ferreira, I. A. T. M., Goonawardane, N., Saito, A., Kimura, I., Yamasoba, D., Gerber, P. P., Fatihi, S., Rathore, S., et al. (2022) · Nature · doi:10.1038/s41586-022-04474-x · Cited by 1,146 · see citing works
Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift
Cameroni, E., Bowen, J. E., Rosen, L. E., Saliba, C., Zepeda, S. K., Culap, K., Pinto, D., VanBlargan, L. A., Marco, A. D., di Iulio, J., et al. (2021) · Nature · doi:10.1038/s41586-021-04386-2 · Cited by 1,043 · see citing works
Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa
Pulliam, J. R. C., van Schalkwyk, C., Govender, N., Gottberg, A. V., Cohen, C., Groome, M. J., Dushoff, J., Mlisana, K., & Moultrie, H. (2021) · doi:10.1101/2021.11.11.21266068 · Cited by 1,037 · see citing works
Proteomics of SARS-CoV-2-infected host cells reveals therapy targets
Bojkova, D., Klann, K., Koch, B., Widera, M., Krause, D., Ciesek, S., Cinatl, J., & Münch, C. (2020) · Nature · doi:10.1038/s41586-020-2332-7 · Cited by 1,010 · see citing works
Self-citationSARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies
Hoffmann, M., Arora, P., Groß, R., Seidel, A., Hörnich, B. F., Hahn, A. S., Krüger, N., Graichen, L., Hofmann-Winkler, H., Kempf, A., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.036 · Cited by 897 · see citing works
Chen, R. E., Zhang, X., Case, J. B., Winkler, E. S., Liu, Y., VanBlargan, L. A., Liu, J., Errico, J. M., Xie, X., Suryadevara, N., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01294-w · Cited by 881 · see citing works
Antibody evasion properties of SARS-CoV-2 Omicron sublineages
Iketani, S., Liu, L., Guo, Y., Liu, L., Chan, J. F., Huang, Y., Wang, M., Luo, Y., Yu, J., Chu, H., et al. (2022) · Nature · doi:10.1038/s41586-022-04594-4 · Cited by 773 · see citing works
THE METHOD OF ‘RIGHT AND WRONG CASES’ (‘CONSTANT STIMULI’) WITHOUT GAUSS'S FORMULAE
Spearman, C. (1908) · British Journal of Psychology 1904-1920 · doi:10.1111/j.2044-8295.1908.tb00176.x · Cited by 745 · see citing works
SARS-CoV-2 B.1.1.7 sensitivity to mRNA vaccine-elicited, convalescent and monoclonal antibodies
Collier, D. A., De Marco, A., Ferreira, I. A. T. M., Meng, B., Datir, R., Walls, A. C., Kemp S, S. A., Bassi, J., Pinto, D., Fregni, C. S., et al. (2021) · doi:10.1101/2021.01.19.21249840 · Cited by 729 · see citing works
Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies
Collier, D. A., De Marco, A., Ferreira, I. A. T. M., Meng, B., Datir, R. P., Walls, A. C., Kemp, S. A., Bassi, J., Pinto, D., Silacci-Fregni, C., et al. (2021) · Nature · doi:10.1038/s41586-021-03412-7 · Cited by 728 · see citing works
VanBlargan, L. A., Errico, J. M., Halfmann, P., Zost, S. J., Crowe, J. E., Purcell, L. A., Kawaoka, Y., Corti, D., Fremont, D. H., & Diamond, M. (2022) · Nature Medicine · doi:10.1038/s41591-021-01678-y · Cited by 676 · see citing works
Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum
Liu, C., Ginn, H. M., Dejnirattisai, W., Supasa, P., Wang, B., Tuekprakhon, A., Nutalai, R., Zhou, D., Mentzer, A. J., Zhao, Y., et al. (2021) · Cell · doi:10.1016/j.cell.2021.06.020 · Cited by 669 · see citing works
SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters
Halfmann, P., Iida, S., Iwatsuki‐Horimoto, K., Maemura, T., Kiso, M., Scheaffer, S. M., Darling, T. L., Joshi, A., Loeber, S. J., Singh, G., et al. (2022) · Nature · doi:10.1038/s41586-022-04441-6 · Cited by 654 · see citing works
Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron
Shuai, H., Chan, J. F.-W., Hu, B., Chai, Y., Yuen, T. T.-T., Yin, F., Huang, X., Yoon, C., Hu, J., Liu, H., et al. (2022) · Nature · doi:10.1038/s41586-022-04442-5 · Cited by 637 · see citing works
SARS-CoV-2 Omicron variant: Antibody evasion and cryo-EM structure of spike protein–ACE2 complex
Mannar, D., Saville, J. W., Zhu, X., Srivastava, S. S., Berezuk, A. M., Tuttle, K. S., Marquez, A. C., Sekirov, I., & Subramaniam, S. (2022) · Science · doi:10.1126/science.abn7760 · Cited by 630 · see citing works
T cell responses to SARS-CoV-2 spike cross-recognize Omicron
Keeton, R. S., Tincho, M. B., Ngomti, A., Baguma, R., Benede, N., Suzuki, A., Khan, K., Cele, S., Bernstein, M. P., Karim, F., et al. (2022) · Nature · doi:10.1038/s41586-022-04460-3 · Cited by 611 · see citing works
mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection
Stamatatos, L., Czartoski, J., Wan, Y.-H., Homad, L. J., Rubin, V., Glantz, H., Neradilek, M., Seydoux, E., Jennewein, M. F., MacCamy, A. J., et al. (2021) · Science · doi:10.1126/science.abg9175 · Cited by 557 · see citing works
Effectiveness of mRNA-1273 against SARS-CoV-2 omicron and delta variants
Tseng, H. F., Ackerson, B. K., Luo, Y., Sy, L. S., Talarico, C. A., Tian, Y., Bruxvoort, K. J., Tubert, J. E., Florea, A., Ku, J. H., et al. (2022) · doi:10.1101/2022.01.07.22268919 · Cited by 541 · see citing works
SARS-CoV-2 Omicron Variant Neutralization in Serum from Vaccinated and Convalescent Persons
Rössler, A., Riepler, L., Bante, D., von Laer, D., & Kimpel, J. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2119236 · Cited by 466 · see citing works
Syncytia formation by SARS‐CoV‐2‐infected cells
Buchrieser, J., Dufloo, J., Hubert, M., Monel, B., Planas, D., Rajah, M. M., Planchais, C., Porrot, F., Guivel‐Benhassine, F., Van der Werf, S., et al. (2020) · The EMBO Journal · doi:10.15252/embj.2020106267 · Cited by 462 · see citing works
Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron
Carreño, J. M., Alshammary, H., Tcheou, J., Singh, G., Raskin, A. J., Kawabata, H., Sominsky, L. A., Clark, J. J., Adelsberg, D. C., Bielak, D. A., et al. (2021) · Nature · doi:10.1038/s41586-022-04399-5 · Cited by 456 · see citing works
Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron
Liu, J., Chandrashekar, A., Sellers, D., Barrett, J., Jacob-Dolan, C., Lifton, M. A., McMahan, K., Sciacca, M., VanWyk, H., Wu, C., et al. (2022) · Nature · doi:10.1038/s41586-022-04465-y · Cited by 451 · see citing works
Ferdinands, J. M., Rao, S., Dixon, B. E., Mitchell, P. K., DeSilva, M. B., Irving, S. A., Lewis, N., Natarajan, K., Stenehjem, E., Grannis, S. J., et al. (2022) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7107e2 · Cited by 435 · see citing works
Divergent SARS-CoV-2 Omicron–reactive T and B cell responses in COVID-19 vaccine recipients
GeurtsvanKessel, C. H., Geers, D., Schmitz, K. S., Mykytyn, A. Z., Lamers, M. M., Bogers, S., Scherbeijn, S. M. J., Gommers, L., Sablerolles, R. S. G., Nieuwkoop, N. N., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abo2202 · Cited by 401 · see citing works
Kustin, T., Harel, N., Finkel, U., Perchik, S., Harari, S., Tahor, M., Caspi, I., Levy, R., Leshchinsky, M., Ken Dror, S., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01413-7 · Cited by 373 · see citing works
Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera
Muik, A., Lui, B. G., Wallisch, A.-K., Bacher, M., Mühl, J., Reinholz, J., Ozhelvaci, O., Beckmann, N., Güimil Garcia, R. D. L. C., Poran, A., et al. (2022) · Science · doi:10.1126/science.abn7591 · Cited by 367 · see citing works
Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum
Dejnirattisai, W., Shaw, R. H., Supasa, P., Liu, C., Stuart, A. S. V., Pollard, A. J., Liu, X., Lambe, T., Crook, D. W., Stuart, D. I., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02844-0 · Cited by 340 · see citing works
Erratum To: Syncytia formation by SARS‐CoV‐2‐infected cells
Buchrieser, J., Dufloo, J., Hubert, M., Monel, B., Planas, D., Rajah, M. M., Planchais, C., Porrot, F., Guivel‐Benhassine, F., van der Werf, S., et al. (2021) · The EMBO Journal · doi:10.15252/embj.2020107405 · Cited by 326 · see citing works
Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose
Kuhlmann, C., Mayer, C. K., Claassen, M., Maponga, T. G., Burgers, W. A., Keeton, R. S., Riou, C., Sutherland, A. D., Suliman, T., Shaw, M. L., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00090-3 · Cited by 323 · see citing works
Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants
Yu, J., Collier, A.-R. Y., Rowe, M., Mardas, F., Ventura, J. D., Wan, H., Miller, J., Powers, O. C., Chung, B., Siamatu, M., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2201849 · Cited by 322 · see citing works
Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection
Cromer, D., Juno, J. A., Khoury, D., Reynaldi, A., Wheatley, A. K., Kent, S. J., & Davenport, M. P. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00550-x · Cited by 265 · see citing works
SARS-CoV-2 vaccine protection and deaths among US veterans during 2021
Cohn, B. A., Cirillo, P. M., Murphy, C. C., Krigbaum, N. Y., & Wallace, A. W. (2021) · Science · doi:10.1126/science.abm0620 · Cited by 242 · see citing works
Antibody-Dependent Cellular Phagocytosis in Antiviral Immune Responses
Tay, M. Z., Wiehe, K. J., & Pollara, J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00332 · Cited by 229 · see citing works
Sequence analysis of the emerging SARS‐CoV‐2 variant Omicron in South Africa
Wang, L., & Cheng, G. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27516 · Cited by 221 · see citing works
Neutralization of the SARS-CoV-2 Mu Variant by Convalescent and Vaccine Serum
Uriu, K., Kimura, I., Shirakawa, K., Takaori-Kondo, A., Nakada, T.-A., Kaneda, A., Nakagawa, S., & Sato, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2114706 · Cited by 214 · see citing works
Cathcart, A. L., Havenar‐Daughton, C., Lempp, F. A., Ma, D., Schmid, M., Agostini, M. L., Guarino, B., di Iulio, J., Rosen, L. E., Tucker, H., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.09.434607 · Cited by 206 · see citing works
Reduced pathogenicity of the SARS-CoV-2 omicron variant in hamsters
McMahan, K., Giffin, V. M., Tostanoski, L. H., Chung, B., Siamatu, M., Suthar, M. S., Halfmann, P., Kawaoka, Y., Piedra-Mora, C., Jain, N., et al. (2022) · Med · doi:10.1016/j.medj.2022.03.004 · Cited by 190 · see citing works
Immune response to SARS-CoV-2 variants of concern in vaccinated individuals
Becker, M., Dulovic, A., Junker, D., Ruétalo, N., Kaiser, P. D., Pinilla, Y. T., Heinzel, C., Häring, J., Traenkle, B., Wagner, T. R., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23473-6 · Cited by 135 · see citing works
Mapping SARS-CoV-2 antigenic relationships and serological responses
Wilks, S. H., Mühlemann, B., Shen, X., Türeli, S., LeGresley, E. B., Netzl, A., Caniza, M. A., Chacaltana-Huarcaya, J. N., Corman, V. M., Daniell, X. G., et al. (2023) · Science · doi:10.1126/science.adj0070 · Cited by 134 · see citing works
Grabowski, F., Kochańczyk, M., & Lipniacki, T. (2022) · Viruses · doi:10.3390/v14020294 · Cited by 121 · see citing works
Antibody-dependent cellular cytotoxicity response to SARS-CoV-2 in COVID-19 patients
Yu, Y.-L., Wang, M., Zhang, X.-A., Li, S.-F., Lu, Q.-Y., Zeng, H.-L., Hou, H., Li, H., Zhang, M.-Y., Jiang, F., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00759-1 · Cited by 108 · see citing works
Infection of cultured intestinal epithelial cells with severe acute respiratory syndrome coronavirus
Cinatl, J. J., Hoever, G., Morgenstern, B., Preiser, W., Vogel, J., Hofmann, W.-K., Bauer, G., Michaelis, M., Rabenau, H. F., & Doerr, H. W. (2004) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-004-4222-9 · Cited by 86 · see citing works
COVID-19 Vaccines: “Warp Speed” Needs Mind Melds, Not Warped Minds
Moore, J. P., & Klasse, P. J. (2020) · Journal of Virology · doi:10.1128/jvi.01083-20 · Cited by 86 · see citing works
Wilhelm, A., Toptan, T., Pallas, C., Wolf, T., Goetsch, U., Gottschalk, R., Vehreschild, M. J. G. T., Ciesek, S., & Widera, M. (2021) · Viruses · doi:10.3390/v13091693 · Cited by 86 · see citing works
Self-citationWidera, M., Wilhelm, A., Hoehl, S., Pallas, C., Kohmer, N., Wolf, T., Rabenau, H. F., Corman, V. M., Drosten, C., Vehreschild, M. J. G. T., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab355 · Cited by 81 · see citing works
Self-citationOptimized qRT-PCR Approach for the Detection of Intra- and Extra-Cellular SARS-CoV-2 RNAs
Toptan, T., Hoehl, S., Westhaus, S., Bojková, D., Berger, A., Rotter, B., Hoffmeier, K., Cinatl, J. J., Ciesek, S., & Widera, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124396 · Cited by 80 · see citing works
Self-citationMutational and phylogenetic analyses of the two lineages of the Omicron variant
Majumdar, S., & Sarkar, R. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27558 · Cited by 71 · see citing works
Romero‐Olmedo, A. J., Schulz, A. R., Hochstätter, S., Gupta, D. D., Virta, I., Hirseland, H., Staudenraus, D., Camara, B., Münch, C., Hefter, V., et al. (2022) · Nature Microbiology · doi:10.1038/s41564-021-01046-z · Cited by 69 · see citing works
Self-citationPresence of antibody-dependent cellular cytotoxicity (ADCC) against SARS-CoV-2 in COVID-19 plasma
Tso, F. Y., Lidenge, S. J., Poppe, L. K., Peña, P. B., Privatt, S. R., Bennett, S. J., Ngowi, J. R., Mwaiselage, J., Belshan, M., Siedlik, J. A., et al. (2021) · PLOS ONE · doi:10.1371/journal.pone.0247640 · Cited by 68 · see citing works
Mapping SARS-CoV-2 antigenic relationships and serological responsesPreprint
Wilks, S., Mühlemann, B., Shen, X., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.01.28.477987 · Cited by 59 · see citing works
Evaluation of stability and inactivation methods of SARS-CoV-2 in context of laboratory settings
Widera, M., Westhaus, S., Rabenau, H. F., Hoehl, S., Bojková, D., Cinatl, J. J., & Ciesek, S. (2021) · Medical Microbiology and Immunology · doi:10.1007/s00430-021-00716-3 · Cited by 41 · see citing works
Self-citationWidera, M., Wilhelm, A., Toptan, T., Raffel, J. M., Kowarz, E., Roesmann, F., Grözinger, F., Siemund, A. L., Luciano, V., Külp, M., et al. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.701198 · Cited by 41 · see citing works
Self-citationWidera, M., Mühlemann, B., Corman, V. M., Toptan, T., Beheim-Schwarzbach, J., Kohmer, N., Schneider, J. A., Berger, A., Veith, T., Pallas, C., et al. (2021) · Microorganisms · doi:10.3390/microorganisms9040748 · Cited by 13 · see citing works
Self-citationDelbrück, M., Hoehl, S., Toptan, T., Schenk, B., Grikscheit, K., Metzler, M., Herrmann, E. M., & Ciesek, S. (2022) · Frontiers in Aging · doi:10.3389/fragi.2022.883724 · Cited by 13 · see citing works
Self-citation
Flagged first, then by citations
Research works printed but not linked: 1
- [15]Cele S Jackson L Khoury DS Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization Nature 602 7898 2022 654 656 35016196 PMC8866126
Cited by
Sorted by citations
Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern
Andrews, N., Stowe, J., Kirsebom, F., Toffa, S., Rickeard, T., Gallagher, E., Gower, C., Kall, M., Groves, N., O’Connell, A.-M., et al. (2021) · doi:10.1101/2021.12.14.21267615 · Cited by 2,420 · see citing works
Cele, S., Jackson, L., Khoury, D. S., Khan, K., Moyo-Gwete, T., Tegally, H., San, J. E., Cromer, D., Scheepers, C., Amoako, D., et al. (2021) · doi:10.1101/2021.12.08.21267417 · Cited by 1,333 · see citing works
Effectiveness of mRNA-1273 against SARS-CoV-2 omicron and delta variants
Tseng, H. F., Ackerson, B. K., Luo, Y., Sy, L. S., Talarico, C. A., Tian, Y., Bruxvoort, K. J., Tubert, J. E., Florea, A., Ku, J. H., et al. (2022) · doi:10.1101/2022.01.07.22268919 · Cited by 541 · see citing works
Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera
Muik, A., Lui, B. G., Wallisch, A.-K., Bacher, M., Mühl, J., Reinholz, J., Ozhelvaci, O., Beckmann, N., Güimil Garcia, R. D. L. C., Poran, A., et al. (2022) · Science · doi:10.1126/science.abn7591 · Cited by 367 · see citing works
Stowe, J., Andrews, N., Kirsebom, F., Ramsay, M., & Bernal, J. L. (2022) · Nature Communications · doi:10.1038/s41467-022-33378-7 · Cited by 166 · see citing works
Buchan, S. A., Chung, H., Brown, K. A., Austin, P. C., Fell, D. B., Gubbay, J. B., Nasreen, S., Schwartz, K. L., Sundaram, M. E., Tadrous, M., et al. (2022) · doi:10.1101/2021.12.30.21268565 · Cited by 356 · see citing works
Adams, K., Rhoads, J. P., Surie, D., Gaglani, M., Ginde, A. A., McNeal, T., Talbot, H. K., Casey, J. D., Zepeski, A., Shapiro, N. I., et al. (2022) · BMJ · doi:10.1136/bmj-2022-072065 · Cited by 115 · see citing works
Florentino, P. T. V., Millington, T., Cerqueira-Silva, T., Robertson, C., de Araújo Oliveira, V., Júnior, J. B. S., Alves, F. J. O., Penna, G. O., Vital Katikireddi, S., Boaventura, V. S., et al. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00451-0 · Cited by 55 · see citing works
Bounding the levels of transmissibility & immune evasion of the Omicron variant in South Africa
Pearson, C. A. B., Silal, S. P., Li, M. W. Z., Dushoff, J., Bolker, B. M., Abbott, S., van Schalkwyk, C., Davies, N. G., Barnard, R. C., Edmunds, W. J., et al. (2021) · doi:10.1101/2021.12.19.21268038 · Cited by 44 · see citing works
Corleis, B., Hoffmann, D., Rauch, S., Fricke, C., Roth, N., Gergen, J., Kovacikova, K., Schlottau, K., Halwe, N. J., Ulrich, L., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36110-1 · Cited by 22 · see citing works
Self-citationMeggiolaro, A., Sane Schepisi, M., Farina, S., Castagna, C., Mammone, A., Siddu, A., Stefanelli, P., Boccia, S., & Rezza, G. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2130773 · Cited by 17 · see citing works
- Authors
- Wilhelm, A., Widera, M., Grikscheit, K., Toptan, T., Schenk, B., Pallas, C., Metzler, M., Kohmer, N., Hoehl, S., Helfritz, F. A., Wolf, T., Goetsch, U., & Ciesek, S.
- Affiliations
- Goethe University Frankfurt (DE)
- Bürgerhospital Frankfurt am Main (DE)
- Corresponding author
- Widera, Marek
- Ciesek, Sandra
- ORCID
- Venue
- EBioMedicine
- Publisher
- openRxiv
- Published
- 2021-12-08
- Volume
- 82
- Pages
- 104158-104158
- ISSN
- 2352-3964 (ISSN-L)
- PMC
- PMC9271884
- OpenAlex
- W4285023345
- Cited by
- 440
- References
- 67
- Citations by year
- 2026: 8 · 2025: 10 · 2024: 30 · 2023: 93 · 2022: 260 · 2021: 39
- FWCI
- 48.03
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- EBioMedicine (publishedVersion, cc-by-nc-nd)
- medRxiv (acceptedVersion, cc-by-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Fraunhofer-Publica (Fraunhofer-Gesellschaft) (submittedVersion)
- Publication Server of Goethe University Frankfurt am Main (Goethe University Frankfurt) (submittedVersion, cc-by-nd)
- Publication Server of Goethe University Frankfurt am Main (Goethe University Frankfurt) (submittedVersion, cc-by-nc-nd)
- Funders
- Bundesministerium für Bildung und Forschung (SARS-CoV-2, 02WRS1621C)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
- Keywords
- SARS-CoV-2 Omicron subvariants, BA.1, BA.2, neutralizing antibodies, waning immunity, vaccine escape, convalescent serum, monoclonal antibodies, casirivimab/imdevimab, sotrovimab, spike protein mutations, breakthrough infection
- MeSH terms
- COVID-19, SARS-CoV-2, BNT162 Vaccine, COVID-19 Serotherapy, Antibodies, Monoclonal, Antibodies, Viral, Humans, Immunization, Passive, Viral Vaccines, Antibodies, Neutralizing, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
